{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:44:01Z","timestamp":1785386641775,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>The use of EZH2 inhibitor tazematostat in early phase clinical trials has proved encouraging in the treatment of follicular lymphoma harbouring an EZH2 mutation; however, responses are also seen in patients with wild-type disease which is partially explained by the off target effects of EZH2 inhibition on immune cells within the tumour microenvironment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Further studies incorporating prospective molecular profiling are needed to allow stratification of patients at both diagnosis and relapse to further our understanding of how epigenetic modifier mutations evolve over time. The use of tazematostat in combination or upfront in patients with an EZH2 mutation remains unanswered; however, given durable responses, ease of oral administration, and tolerability, it is certainly an attractive option.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-021-01076-0","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T21:04:20Z","timestamp":1620075860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches\u2014Focus on EZH2-Targeted Drugs"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-0686","authenticated-orcid":false,"given":"Jemma","family":"Longley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"1","key":"1076_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/epi.15.96","volume":"8","author":"S Araf","year":"2016","unstructured":"Araf S, Okosun J, Koniali L, Fitzgibbon J, Heward J. Epigenetic dysregulation in follicular lymphoma. Epigenomics. 2016;8(1):77\u201384.","journal-title":"Epigenomics"},{"key":"1076_CR2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3389\/fgene.2019.00986","volume":"10","author":"ML Ribeiro","year":"2019","unstructured":"Ribeiro ML, Reyes-Garau D, Armengol M, Fern\u00e1ndez-Serrano M, Rou\u00e9 G. Recent advances in the targeting of epigenetic regulators in B-cell non-hodgkin lymphoma. Front Genet. 2019;10:986.","journal-title":"Front Genet"},{"issue":"5","key":"1076_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"\u2022 Italiano A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649\u201359. Phase I study highlighting activity of taemetostat in lymphoma.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1076_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.canlet.2016.01.036","volume":"373","author":"C-Y Yen","year":"2016","unstructured":"Yen C-Y, Huang HW, Shu CW, Hou MF, Yuan SSF, Wang HR, et al. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers. Cancer Lett. 2016;373(2):185\u201392.","journal-title":"Cancer Lett"},{"issue":"1","key":"1076_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/imr.12745","volume":"288","author":"L Pasqualucci","year":"2019","unstructured":"Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol Rev. 2019;288(1):240\u201361.","journal-title":"Immunol Rev"},{"issue":"5","key":"1076_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","volume":"37","author":"W B\u00e9guelin","year":"2020","unstructured":"B\u00e9guelin W, et al. Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell. 2020;37(5):655\u2013673.e11.","journal-title":"Cancer Cell"},{"issue":"6","key":"1076_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"\u2022\u2022 Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018;131(6):595\u2013604. Demonstration of the effects of mutant EZH2 in the microenvironment of lymphoma as a possible explanation of the mechanism of action of EZH2 inhibitors in WT lymphomas.","journal-title":"Blood"},{"key":"1076_CR8","doi-asserted-by":"crossref","unstructured":"Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589(7841):299\u2013305.","DOI":"10.1038\/s41586-020-3017-y"},{"issue":"4","key":"1076_CR9","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7(4):e555.","journal-title":"Blood Cancer J"},{"issue":"18","key":"1076_CR10","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C Bodor","year":"2013","unstructured":"Bodor C, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165\u20138.","journal-title":"Blood"},{"issue":"3","key":"1076_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/0008-5472.CAN-17-1229","volume":"78","author":"D Chowell","year":"2018","unstructured":"Chowell D, Napier J, Gupta R, Anderson KS, Maley CC, Sayres MAW. Modeling the subclonal evolution of cancer cell populations. Cancer Res. 2018;78(3):830\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"1076_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"\u2022 Ennishi D, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9(4):546\u201363. Effects of EZH2 inhibition on immune competence as a possible mechanism of action for inhibitors.","journal-title":"Cancer Discov"},{"issue":"15","key":"1076_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4155\/fmc-2020-0072","volume":"12","author":"J Qiu","year":"2020","unstructured":"Qiu J, Sharma S, Rollins RA, Paul TA. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020;12(15):1415\u201330.","journal-title":"Future Med Chem"},{"issue":"4","key":"1076_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2017.03.012","volume":"46","author":"SM Gray","year":"2017","unstructured":"\u2022\u2022 Gray SM, et al. Polycomb repressive complex 2-mediated chromatin repression guides effector CD8+ T cell terminal differentiation and loss of multipotency. Immunity. 2017;46(4):596\u2013608. Demonstration of the effects of PRC2 modulation on cytotoxic T-cell function.","journal-title":"Immunity"},{"issue":"1","key":"1076_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41467-017-02187-8","volume":"8","author":"S He","year":"2017","unstructured":"He S, Liu Y, Meng L, Sun H, Wang Y, Ji Y, et al. Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. Nat Commun. 2017;8(1):2125.","journal-title":"Nat Commun"},{"issue":"11","key":"1076_CR16","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 2018;23(11):3262\u201374.","journal-title":"Cell Rep"},{"key":"1076_CR17","doi-asserted-by":"crossref","unstructured":"Hamaidia M, Gazon H, Hoyos C, Hoffmann GB, Louis R, Duysinx B, et al. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight. 2019;4(18).","DOI":"10.1172\/jci.insight.128474"},{"issue":"6","key":"1076_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.12819","volume":"165","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014;165(6):768\u201376.","journal-title":"Br J Haematol"},{"issue":"3","key":"1076_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjh.14698","volume":"178","author":"CL Batlevi","year":"2017","unstructured":"Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017;178(3):434\u201341.","journal-title":"Br J Haematol"},{"issue":"24","key":"1076_CR20","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor gsk2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res. 2019;25(24):7331\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1076_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"\u2022\u2022 Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342. Phase II study demonstrating differential efficacy of tazemetostat in MT and WT FL.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1076_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3324\/haematol.2014.117473","volume":"100","author":"R Chen","year":"2015","unstructured":"Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015;100(3):357\u201362.","journal-title":"Haematologica"},{"issue":"17","key":"1076_CR23","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","volume":"25","author":"JK Lue","year":"2019","unstructured":"Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, et al. Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin Cancer Res. 2019;25(17):5271\u201383.","journal-title":"Clin Cancer Res"},{"issue":"S2","key":"1076_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hon.203_2631","volume":"37","author":"ML Palomba","year":"2019","unstructured":"Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Chitra S, et al. Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large b-cell lymphoma: primary analysis of a phase 1B sTUDY. Hematol Oncol. 2019;37(S2):517\u20139.","journal-title":"Hematol Oncol"},{"issue":"Supplement_1","key":"1076_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood-2019-130208","volume":"134","author":"V Jurinovic","year":"2019","unstructured":"Jurinovic V, et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134(Supplement_1):122.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01076-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T14:42:24Z","timestamp":1623940944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01076-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01076-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jemma Longley declares that she has no conflict of interest. Peter W.M. Johnson has received research funding from Epizyme and Janssen, and has received compensation for service as a consultant from Epizyme, Janssen, Takeda, Bristol-Myers Squibb, Novartis, Celgene, Boehringer Ingelheim, Kite Pharma, Genmab, Incyte Corporation, MorphoSys, and Kymera Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"76"}}